NOTE: This order is nonprecedential.

# United States Court of Appeals for the Federal Circuit

# HOFFMANN-LA ROCHE INC.,

Plaintiff-Appellant,

 $\mathbf{v}_{i}$ 

# TEVA PHARMACEUTICALS USA, INC. AND TEVA PHARMACEUTICAL INDUSTRIES LTD.,

Defendants-Appellees.

2012-1131	

Appeal from the United States District Court for the District of New Jersey in case no. 09-CV-5283, Judge Esther Salas.

## HOFFMANN-LA ROCHE INC.,

Plaintiff-Appellant,

v.

ACCORD HEALTHCARE INC. AND INTAS PHARMACEUTICAL LTD.,

Defendants-Appellees.

#### 2012-1195

Appeal from the United States District Court for the District of New Jersey in case no. 11-CV-1192, Judge Esther Salas.

### ON MOTION

#### ORDER

Hoffmann-La Roche Inc. moves to consolidate the above-captioned appeals.\* Teva Pharmaceuticals USA, Inc. et al. (Teva) oppose. Accord Healthcare Inc. et al. (Accord) oppose consolidation and move to stay appeal no. 2012-1195 pending appeal no. 2012-1131 stating they agree to be bound by this court's decision in 2012-1131. Hoffmann-La Roche replies and consents to a stay of 2012-1195. Hoffmann-La Roche moves for an extension of time, until May 9, 2012, to file its opening brief in 2012-1131. Teva opposes. Hoffmann La Roche replies. Hoffmann La Roche also moves without opposition for an extension of time to file its opening brief in 2012-1195.

Upon consideration thereof,

IT IS ORDERED THAT:

(1) The motion to consolidate is denied.

<sup>\*</sup> Hoffmann La Roche also moved to consolidate these appeals with *Hoffmann-La Roche v. Roxane Labs*, No. 2012-1132, but this court subsequently granted Hoffmann LaRoche's motion to voluntarily dismiss that appeal.

- (2) Appeal no. 2012-1195 is stayed pending issuance of the mandate in appeal no. 2012-1131. Within 14 days thereof, Hoffmann La Roche and Accord are directed to inform this court concerning how they believe 2012-1195 should proceed.
- (3) A copy of this order will be forwarded to the merits panel in appeal no. 2012-1131.
- (4) Hoffmann La Roche's motion for an extension of time is granted.
- (5) Teva shall calculate the due date for its response brief from the date of filing of this order.
- (6) Hoffmann La Roche's motion for an extension of time in 2012-1195 is most in light of the stay.

FOR THE COURT

MAY 2 1 2012

Date

/s/ Jan Horbaly Jan Horbaly Clerk

cc: Brian D. Coggio, Esq. Jeffer Ali, Esq. Kenneth G. Schuler, Esq. Michael R. Dzwonczyk, Esq.

FILED U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT

MAY 2 1 2012

JAN HORBALY CLERK

s25